Richard R. Furman - Concepedia

Author

Richard R. Furman

Also Known As

N. Sheerin, R Furman, R R Furman, R. Furman, R. R. Furman, R.R. Furman, Richard Furman, Richard R Furman, Richard R. Furman, Richard R. Furman

494

Publications

32.8K

Citations

H-Index

114

Concepts

All Affiliations

Cornell University The University of Texas MD Anderson Cancer Center The Ohio State University Stanford University NewYork–Presbyterian Hospital

About

Richard R. Furman is an author at Cornell University specializing in medicine, immunology, and pathology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	35	75	5K
2	Health Sciences	18	28	1.3K
3	Allergy	4	4	173
4	Natural Sciences	1	1	84
5	Public Health	1	1	66

Richard R. Furman

220

Publications

30.9K

Citations

H-Index

Page 1

	Year	Citations
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia John C. Byrd, Richard R. Furman, Steven Coutré, New England Journal of Medicine	2013	2.2K
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia Richard R. Furman, Jeff P. Sharman, Steven Coutré, New England Journal of Medicine	2014	1.7K
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia John C. Byrd, Jennifer R. Brown, Susan O’Brien, New England Journal of Medicine	2014	1.6K
Terminal Complement Inhibitor Eculizumab in Atypical Hemolytic–Uremic Syndrome Christophe Legendre, Christoph Licht, Petra Muus, New England Journal of Medicine	2013	1.5K
Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Jennifer A. Woyach, Richard R. Furman, Ta-Ming Liu, New England Journal of Medicine	2014	1.2K
Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies Ranjana H. Advani, Joseph J. Buggy, Jeff P. Sharman, Journal of Clinical Oncology	2012	1.1K
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia John C. Byrd, Bonnie K. Harrington, Susan O’Brien, New England Journal of Medicine	2015	878
Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project Kenneth R. Carson, Andrew M. Evens, Elizabeth Richey, Blood	2009	866
Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes Jason A. Dubovsky, Kyle A. Beckwith, Gayathri Natarajan, Blood	2013	783
Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib John C. Byrd, Richard R. Furman, Steven Coutré, Blood	2015	653

Page 1